Benign-appearing masses in male patients should be approached thoughtfully, given the overlapping morphologic features of benign and malignant tumors. In addition to gynecomastia, other benign male breast tumors include lipoma, pseudoangiomatous stromal hyperplasia, granular cell tumor, fibromatosis, myofibroblastoma, schwannoma, and hemangioma.1 Diseases in the male breast can affect any component of the normal breast anatomy, including the skin, subcutaneous fat, stroma, glands, neurovascular structures, and lymphatic vessels. Typically, fat makes up most of the breast volume in men, with few residual ducts and stroma due to involution and atrophy from androgenic antagonistic effects.2
Present cases of male patients presenting with solid breast masses as well as the radiologic and clinical management.
This is a case series of 12 solid breast masses identified in male patients who did not receive a breast cancer diagnosis. We will discuss the patient presentation, imaging findings, and histopathological appearance. Surgical or clinical management recommendations, when available, will also be presented.
Solid breast masses in male patients should be evaluated thoroughly to exclude malignancy, given the overlapping features of benign and malignant tumors. This could include clinical evaluation and thorough history, imaging and/or tissue sampling, and possible surgical consultation and/or excision.
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer
Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
This study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.